


Zotarolimus

Cat. No.:	HY-12424		
CAS No.:	221877-54-9		
Molecular Formula:	C ₅₂ H ₇₉ N ₅ O ₁₂		
Molecular Weight:	966.21		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (103.50 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.0350 mL	5.1749 mL	10.3497 mL
	5 mM	0.2070 mL	1.0350 mL	2.0699 mL
	10 mM	0.1035 mL	0.5175 mL	1.0350 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (2.59 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.59 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis^{[1][2]}.

CUSTOMER VALIDATION

- J Cell Sci. 2019 May 20;132(10):jcs227777.

-
- Acta Trop. 2020 Dec;212:105708.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Sandra E Burke, et al. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev. 2006 Jun 3;58(3):437-46.
- [2]. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA